Physician profile
Mandeep Singh
NPI 1285949537
$3,887.87
in general payments reported to CMS, 2019-2025
23 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $492 · 2023: $683 · 2024: $1,394 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $927.19 | 2022-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.04 | 2021-2025 | Ofev |
| United Therapeutics Corporation | $418.48 | 2022-2025 | Tyvaso, Orenitram, Tyvaso |
| Glaxosmithkline, LLC. | $383.35 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $272.28 | 2023-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $162.66 | 2024-2025 | Winrevair |
| Electromed, INC. | $158.13 | 2021-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $133.36 | 2022-2025 | Dupixent |
| Abbvie INC. | $123.98 | 2024-2025 | |
| Insmed, INC. | $109.12 | 2023-2025 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $106.02 | 2023-2025 | |
| Genzyme Corporation | $101.23 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $100.11 | 2022-2024 | Opsumit |
| Mylan Specialty L.P. | $92.00 | 2022-2024 | Yupelri |
| Grifols USA, LLC | $82.20 | 2021-2025 | Prolastin-C Liquid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $61.65 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Idorsia Pharmaceuticals US INC | $36.64 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $34.61 | 2022-2023 | |
| Pulmonx Corporation | $24.22 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Viatris Specialty LLC | $23.11 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $18.12 | 2024 | Xarelto |
| Verona Pharma, INC. | $15.51 | 2025 | Ohtuvayre |
| Mayne Pharma Commercial LLC | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.